MB04 (etanercept biosimilar) / Insud Pharma 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MB04 (etanercept biosimilar) / Insud Pharma
NCT06596772: A Study to Compare Efficacy, Pharmacokinetics, Safety and Immunogenicity of MB04 [proposed Etanercept Biosimilar] to Enbrel® [EU-sourced] in Rheumatoid Arthritis

Recruiting
3
458
RoW
MB04 (proposed biosimilar to etanercept), Enbrel (etanercept)
mAbxience Research S.L.
Rheumatoid Arthritis (RA)
10/25
01/26
MB04-A-01-23, NCT06392074: A Study Investigating the Safety, Absorption, and Elimination of MB04, a New Compound That May Potentially Be Used in the Treatment of Autoimmune Disorders

Active, not recruiting
1
132
Europe
MB04, (etanercept biosimilar), US License Enbrel, (etanercept), EU Source Enbrel
mAbxience Research S.L.
Healthy Volunteers
09/24
12/24

Download Options